Next Article in Journal
Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
Next Article in Special Issue
Allogeneic HLA Humoral Immunogenicity and the Prediction of Donor-Specific HLA Antibody Development
Previous Article in Journal
Humanization of Pan-HLA-DR mAb 44H10 Hinges on Critical Residues in the Antibody Framework
Previous Article in Special Issue
Beyond bNAbs: Uses, Risks, and Opportunities for Therapeutic Application of Non-Neutralising Antibodies in Viral Infection
 
 
Review

Article Versions Notes

Antibodies 2024, 13(3), 58; https://doi.org/10.3390/antib13030058
Action Date Notes Link
article xml file uploaded 16 July 2024 12:19 CEST Original file -
article xml uploaded. 16 July 2024 12:19 CEST Update https://www.mdpi.com/2073-4468/13/3/58/xml
article pdf uploaded. 16 July 2024 12:19 CEST Version of Record https://www.mdpi.com/2073-4468/13/3/58/pdf
article html file updated 16 July 2024 12:21 CEST Original file https://www.mdpi.com/2073-4468/13/3/58/html
Back to TopTop